PL2220242T3 - Podrodziny b adenowirusów małpich sadv-28,27,-29,-32,-33, oraz-35 oraz ich wykorzystanie - Google Patents
Podrodziny b adenowirusów małpich sadv-28,27,-29,-32,-33, oraz-35 oraz ich wykorzystanieInfo
- Publication number
- PL2220242T3 PL2220242T3 PL08857781T PL08857781T PL2220242T3 PL 2220242 T3 PL2220242 T3 PL 2220242T3 PL 08857781 T PL08857781 T PL 08857781T PL 08857781 T PL08857781 T PL 08857781T PL 2220242 T3 PL2220242 T3 PL 2220242T3
- Authority
- PL
- Poland
- Prior art keywords
- subfamily
- simian
- sadv
- adenoviruses
- adenoviruses sadv
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/76—Viruses; Subviral particles; Bacteriophages
- A61K35/761—Adenovirus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/162—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10321—Viruses as such, e.g. new isolates, mutants or their genomic sequences
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10332—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10341—Use of virus, viral particle or viral elements as a vector
- C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10351—Methods of production or purification of viral material
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2810/00—Vectors comprising a targeting moiety
- C12N2810/50—Vectors comprising as targeting moiety peptide derived from defined protein
- C12N2810/60—Vectors comprising as targeting moiety peptide derived from defined protein from viruses
- C12N2810/6009—Vectors comprising as targeting moiety peptide derived from defined protein from viruses dsDNA viruses
- C12N2810/6018—Adenoviridae
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Virology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Immunology (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Mycology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US456707P | 2007-11-28 | 2007-11-28 | |
US453107P | 2007-11-28 | 2007-11-28 | |
US453407P | 2007-11-28 | 2007-11-28 | |
US453307P | 2007-11-28 | 2007-11-28 | |
US446607P | 2007-11-28 | 2007-11-28 | |
US454207P | 2007-11-28 | 2007-11-28 |
Publications (1)
Publication Number | Publication Date |
---|---|
PL2220242T3 true PL2220242T3 (pl) | 2017-09-29 |
Family
ID=40718407
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PL08857781T PL2220242T3 (pl) | 2007-11-28 | 2008-11-24 | Podrodziny b adenowirusów małpich sadv-28,27,-29,-32,-33, oraz-35 oraz ich wykorzystanie |
Country Status (20)
Country | Link |
---|---|
US (3) | US8524219B2 (pl) |
EP (1) | EP2220242B1 (pl) |
JP (3) | JP5740157B2 (pl) |
KR (3) | KR101662571B1 (pl) |
CN (1) | CN101883857B (pl) |
AU (2) | AU2008331905B2 (pl) |
BR (1) | BRPI0822651A2 (pl) |
CA (1) | CA2706257C (pl) |
CY (1) | CY1118866T1 (pl) |
DK (1) | DK2220242T3 (pl) |
ES (1) | ES2621165T3 (pl) |
HR (1) | HRP20170395T1 (pl) |
HU (1) | HUE031636T2 (pl) |
LT (1) | LT2220242T (pl) |
MX (2) | MX2010005859A (pl) |
PL (1) | PL2220242T3 (pl) |
PT (1) | PT2220242T (pl) |
SG (2) | SG10201603993TA (pl) |
SI (1) | SI2220242T1 (pl) |
WO (1) | WO2009073103A2 (pl) |
Families Citing this family (51)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DK2220241T3 (en) | 2007-11-28 | 2017-01-09 | Univ Pennsylvania | Adenovirus comprising a simian adenovirus E-SAdV-39-capsidhexonprotein and uses thereof |
JP5661476B2 (ja) * | 2008-03-04 | 2015-01-28 | ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア | サルアデノウイルスSAdV−36、−42.1、−42.2および−44ならびにそれらの用途 |
EP2350269B1 (en) * | 2008-10-31 | 2015-09-09 | The Trustees Of The University Of Pennsylvania | Simian adenoviruses with sadv-46 hexon capsid proteins and uses thereof |
US8846031B2 (en) | 2009-05-29 | 2014-09-30 | The Trustees Of The University Of Pennsylvania | Simian adenovirus 41 and uses thereof |
EP2643465B1 (en) | 2010-11-23 | 2016-05-11 | The Trustees Of The University Of Pennsylvania | Subfamily e simian adenovirus a1321 and uses thereof |
TWI575070B (zh) | 2011-07-12 | 2017-03-21 | 傳斯堅公司 | Hbv聚合酶突變體 |
TW201321016A (zh) | 2011-09-29 | 2013-06-01 | Transgene Sa | 免疫療法組成物及用於治療c型肝炎病毒感染之療程(二) |
TW201318637A (zh) | 2011-09-29 | 2013-05-16 | Transgene Sa | 免疫療法組成物及用於治療c型肝炎病毒感染之療程(一) |
BR112014028684A2 (pt) | 2012-05-18 | 2017-07-25 | Univ Pennsylvania | subfamília e adenovírus de símio a1302, a1320, a1331 e a1337 e usos dos mesmos |
WO2014153204A1 (en) | 2013-03-14 | 2014-09-25 | Salk Institute For Biological Studies | Oncolytic adenovirus compositions |
WO2015191508A1 (en) | 2014-06-09 | 2015-12-17 | Voyager Therapeutics, Inc. | Chimeric capsids |
CN107106689A (zh) | 2014-11-05 | 2017-08-29 | 沃雅戈治疗公司 | 用于治疗帕金森病的aadc多核苷酸 |
MX2017006216A (es) | 2014-11-14 | 2018-08-29 | Voyager Therapeutics Inc | Composiciones y métodos para tratar la esclerosis lateral amiotrófica (ela). |
SG11201703419UA (en) | 2014-11-14 | 2017-05-30 | Voyager Therapeutics Inc | Modulatory polynucleotides |
EP3230441A4 (en) | 2014-12-12 | 2018-10-03 | Voyager Therapeutics, Inc. | Compositions and methods for the production of scaav |
WO2016131945A1 (en) | 2015-02-20 | 2016-08-25 | Transgene Sa | Combination product with autophagy modulator |
CN108025058B (zh) * | 2015-06-12 | 2022-12-16 | 葛兰素史密丝克莱恩生物有限公司 | 腺病毒多核苷酸和多肽 |
EP3384035A4 (en) | 2015-12-02 | 2019-08-07 | Voyager Therapeutics, Inc. | ASSAYS FOR DETECTION OF NEUTRALIZING ANTIBODIES OF VAA |
JP7054527B2 (ja) | 2016-02-23 | 2022-04-14 | ソーク インスティテュート フォー バイオロジカル スタディーズ | アデノウイルスの複製動態を測定するための高スループットアッセイ |
KR20180112024A (ko) | 2016-02-23 | 2018-10-11 | 더 솔크 인스티튜트 포 바이올로지칼 스터디즈 | 바이러스 동역학에 미치는 영향 최소화를 위한 치료용 아데노바이러스의 외인성 유전자 발현 |
US11326182B2 (en) | 2016-04-29 | 2022-05-10 | Voyager Therapeutics, Inc. | Compositions for the treatment of disease |
US11299751B2 (en) | 2016-04-29 | 2022-04-12 | Voyager Therapeutics, Inc. | Compositions for the treatment of disease |
CA3023022A1 (en) | 2016-05-04 | 2017-11-09 | Transgene Sa | Combination therapy with cpg tlr9 ligand |
SG11201809643UA (en) | 2016-05-18 | 2018-12-28 | Voyager Therapeutics Inc | Compositions and methods of treating huntington's disease |
KR102392236B1 (ko) | 2016-05-18 | 2022-05-03 | 보이저 테라퓨틱스, 인크. | 조절성 폴리뉴클레오티드 |
AU2017313917B2 (en) | 2016-08-18 | 2023-12-21 | The Regents Of The University Of California | CRISPR-Cas genome engineering via a modular AAV delivery system |
EP3831281A1 (en) | 2016-08-30 | 2021-06-09 | The Regents of The University of California | Methods for biomedical targeting and delivery and devices and systems for practicing the same |
WO2018069316A2 (en) | 2016-10-10 | 2018-04-19 | Transgene Sa | Immunotherapeutic product and mdsc modulator combination therapy |
CN110062630A (zh) | 2016-12-12 | 2019-07-26 | 萨克生物研究学院 | 肿瘤靶向合成腺病毒及其用途 |
CA3061652A1 (en) | 2017-05-05 | 2018-11-08 | Voyager Therapeutics, Inc. | Compositions and methods of treating amyotrophic lateral sclerosis (als) |
EP3619308A4 (en) | 2017-05-05 | 2021-01-27 | Voyager Therapeutics, Inc. | COMPOSITIONS AND METHODS OF TREATMENT FOR HUNTINGTON'S MORBUS |
JOP20190269A1 (ar) | 2017-06-15 | 2019-11-20 | Voyager Therapeutics Inc | بولي نوكليوتيدات aadc لعلاج مرض باركنسون |
JP7229989B2 (ja) | 2017-07-17 | 2023-02-28 | ボイジャー セラピューティクス インコーポレイテッド | 軌道アレイガイドシステム |
KR20200044793A (ko) | 2017-08-03 | 2020-04-29 | 보이저 테라퓨틱스, 인크. | Aav의 전달을 위한 조성물 및 방법 |
JP7502991B2 (ja) | 2017-10-16 | 2024-06-19 | ボイジャー セラピューティクス インコーポレイテッド | 筋萎縮性側索硬化症(als)の治療 |
WO2019079242A1 (en) | 2017-10-16 | 2019-04-25 | Voyager Therapeutics, Inc. | TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS (ALS) |
WO2019241486A1 (en) | 2018-06-13 | 2019-12-19 | Voyager Therapeutics, Inc. | Engineered 5' untranslated regions (5' utr) for aav production |
JP7413629B2 (ja) | 2018-07-17 | 2024-01-16 | ヘリックスミス カンパニー, リミテッド | Igf-1異型体を発現させるdnaコンストラクトを用いた神経病症の治療 |
CA3107462A1 (en) | 2018-07-24 | 2020-01-30 | Voyager Therapeutics, Inc. | Systems and methods for producing gene therapy formulations |
EP3861113A1 (en) | 2018-10-04 | 2021-08-11 | Voyager Therapeutics, Inc. | Methods for measuring the titer and potency of viral vector particles |
SG11202103425YA (en) | 2018-10-05 | 2021-05-28 | Voyager Therapeutics Inc | Engineered nucleic acid constructs encoding aav production proteins |
EP3867389A1 (en) | 2018-10-15 | 2021-08-25 | Voyager Therapeutics, Inc. | Expression vectors for large-scale production of raav in the baculovirus/sf9 system |
US20230193315A1 (en) | 2019-01-31 | 2023-06-22 | Oregon Health & Science University | Methods for using transcription-dependent directed evolution of aav capsids |
NL2023464B1 (en) * | 2019-07-09 | 2021-02-02 | Academisch Ziekenhuis Leiden | Oncolytic Non-human adenoviruses and uses thereof |
CA3189238A1 (en) | 2020-07-13 | 2022-01-20 | Transgene | Treatment of immune depression |
AU2022214429A1 (en) | 2021-02-01 | 2023-09-14 | Regenxbio Inc. | Gene therapy for neuronal ceroid lipofuscinoses |
WO2022218997A1 (en) | 2021-04-12 | 2022-10-20 | Centre National De La Recherche Scientifique (Cnrs) | Novel universal vaccine presenting system |
WO2023173114A2 (en) * | 2022-03-10 | 2023-09-14 | Technovax, Inc. | Recombinant virus-like particle capsid vaccines against adenoviruses and compositions, methods, and use thereof |
WO2023213764A1 (en) | 2022-05-02 | 2023-11-09 | Transgene | Fusion polypeptide comprising an anti-pd-l1 sdab and a member of the tnfsf |
CN117143833B (zh) * | 2023-08-21 | 2024-06-04 | 暨南大学 | 一种猴腺病毒毒株及其应用 |
CN117089577B (zh) * | 2023-08-21 | 2024-06-25 | 暨南大学 | 重组的猴腺病毒、病毒载体及构建方法 |
Family Cites Families (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2008A (en) * | 1841-03-18 | Gas-lamp eok conducting gas pkom ah elevated buhner to one below it | ||
US2009A (en) * | 1841-03-18 | Improvement in machines for boring war-rockets | ||
US6083716A (en) | 1996-09-06 | 2000-07-04 | The Trustees Of The University Of Pennsylvania | Chimpanzee adenovirus vectors |
AU1822499A (en) | 1997-12-12 | 1999-06-28 | Saint Louis University | Ctip, a novel protein that interacts with ctbp and uses therefor |
US20040136963A1 (en) | 2001-06-22 | 2004-07-15 | The Trustees Of The University Of Pennsylvania | Simian adenovirus vectors and methods of use |
KR20040043129A (ko) * | 2001-06-22 | 2004-05-22 | 더 위스타 인스티튜트 오브 아나토미 앤드 바이올로지 | 세포독성 면역 반응을 유도하는 방법과 그에 유용한재조합체 원숭이 아데노바이러스 조성물 |
US7344872B2 (en) | 2001-06-22 | 2008-03-18 | The Trustees Of The University Of Pennsylvania | Method for rapid screening of bacterial transformants and novel simian adenovirus proteins |
NZ532383A (en) | 2001-11-21 | 2007-03-30 | Univ Pennsylvania | Pan-7 simian adenovirus nucleic acid and amino acid sequences, vectors containing same, and methods of use |
US7291498B2 (en) | 2003-06-20 | 2007-11-06 | The Trustees Of The University Of Pennsylvania | Methods of generating chimeric adenoviruses and uses for such chimeric adenoviruses |
EP1636370B1 (en) * | 2003-06-20 | 2014-04-16 | The Trustees of The University of Pennsylvania | Methods of generating chimeric adenoviruses and uses for such chimeric adenoviruses |
CA2880061C (en) | 2004-01-23 | 2018-03-13 | Agostino Cirillo | Chimpanzee adenovirus vaccine carriers |
US20080004236A1 (en) * | 2004-02-06 | 2008-01-03 | Comper Wayne D | High Dose, Short Interval Use of Sulfated Polysaccharides for Treatment of Infections |
KR20070104881A (ko) * | 2004-10-14 | 2007-10-29 | 크루셀 홀란드 비.브이. | 말라리아 프라임/부스트 백신 |
TW200716750A (en) | 2005-05-12 | 2007-05-01 | Glaxo Group Ltd | Vaccine composition |
DE602007004470D1 (de) | 2006-04-28 | 2010-03-11 | Univ Pennsylvania | Modifiziertes adenovirus-hexon-protein und anwendungen davon |
DK2220241T3 (en) | 2007-11-28 | 2017-01-09 | Univ Pennsylvania | Adenovirus comprising a simian adenovirus E-SAdV-39-capsidhexonprotein and uses thereof |
BRPI0819774A2 (pt) | 2007-11-28 | 2014-10-14 | Univ Pennsylvania | Subfamília c de adenovírus sadv-40, -31 e -34 de símio e seus usos |
-
2008
- 2008-11-24 HU HUE08857781A patent/HUE031636T2/en unknown
- 2008-11-24 WO PCT/US2008/013065 patent/WO2009073103A2/en active Application Filing
- 2008-11-24 SG SG10201603993TA patent/SG10201603993TA/en unknown
- 2008-11-24 ES ES08857781.2T patent/ES2621165T3/es active Active
- 2008-11-24 DK DK08857781.2T patent/DK2220242T3/en active
- 2008-11-24 MX MX2010005859A patent/MX2010005859A/es active IP Right Grant
- 2008-11-24 KR KR1020157025052A patent/KR101662571B1/ko active IP Right Grant
- 2008-11-24 BR BRPI0822651-2A2A patent/BRPI0822651A2/pt not_active Application Discontinuation
- 2008-11-24 CN CN200880118585.XA patent/CN101883857B/zh not_active Expired - Fee Related
- 2008-11-24 CA CA2706257A patent/CA2706257C/en not_active Expired - Fee Related
- 2008-11-24 SI SI200831779A patent/SI2220242T1/sl unknown
- 2008-11-24 US US12/744,375 patent/US8524219B2/en active Active
- 2008-11-24 JP JP2010535986A patent/JP5740157B2/ja not_active Expired - Fee Related
- 2008-11-24 SG SG2012085635A patent/SG186022A1/en unknown
- 2008-11-24 MX MX2013010573A patent/MX344106B/es unknown
- 2008-11-24 KR KR1020167026644A patent/KR101761683B1/ko active IP Right Grant
- 2008-11-24 EP EP08857781.2A patent/EP2220242B1/en not_active Not-in-force
- 2008-11-24 LT LTEP08857781.2T patent/LT2220242T/lt unknown
- 2008-11-24 PL PL08857781T patent/PL2220242T3/pl unknown
- 2008-11-24 KR KR1020107014131A patent/KR101614362B1/ko not_active IP Right Cessation
- 2008-11-24 AU AU2008331905A patent/AU2008331905B2/en not_active Ceased
- 2008-11-24 PT PT88577812T patent/PT2220242T/pt unknown
-
2013
- 2013-08-16 US US13/968,757 patent/US9206238B2/en not_active Expired - Fee Related
-
2014
- 2014-12-05 JP JP2014246762A patent/JP2015107117A/ja active Pending
- 2014-12-16 AU AU2014277699A patent/AU2014277699B2/en not_active Ceased
-
2015
- 2015-11-03 US US14/931,286 patent/US20160051603A1/en not_active Abandoned
-
2016
- 2016-05-18 JP JP2016099658A patent/JP2016214242A/ja active Pending
-
2017
- 2017-03-10 HR HRP20170395TT patent/HRP20170395T1/hr unknown
- 2017-03-28 CY CY20171100382T patent/CY1118866T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PL2220242T3 (pl) | Podrodziny b adenowirusów małpich sadv-28,27,-29,-32,-33, oraz-35 oraz ich wykorzystanie | |
ZA201003895B (en) | Simian subfamily c adenoviruses sadv-40,-31, and -34 and uses thereof | |
EP2108663A4 (en) | POLYMERIZABLE POLYMER, POLYMERIZABLE COMPOSITION AND DENTAL MATERIAL | |
SG10201604001XA (en) | Simian e adenoviruses sadv-39, -25. 2, -26, -30, -37, and -38 | |
ZA200805511B (en) | Levodopa prodrug mesylate, compositions thereof, and uses thereof | |
EP2350269A4 (en) | ADENOVIRUS SIMIENS SADV-43, -45, -48, -49 and 50 and their uses | |
PL2899247T3 (pl) | Kompozycje zawierające 2,3,3,3-tetrafluoropropen i węglowodory oraz ich zastosowania | |
IL211762A0 (en) | Pegylated opiods, compositions comprising the same and uses thereof | |
PL2271725T3 (pl) | Kompozycje zawierające 2,3,3,3-tetrafluoropropen i 1,1,1-trifluoropropen | |
AP2965A (en) | Therapeutic compositions and the use thereof | |
EP2130843A4 (en) | POLYMERIZABLE COMPOUNDS AND POLYMERIZABLE COMPOSITIONS | |
AP2490A (en) | Therapeutic compositions and the use thereof | |
IL184705A0 (en) | Substituted arylamine compounds and their use as 5-ht6 modulators | |
IL240895A0 (en) | Tri-aryl compounds and preparations containing them | |
EP2166058A4 (en) | FRUIT COMPOSITION AND FRUIT THEREOF | |
IL200847A0 (en) | Oligomer-antihistamine inhibitor conjugates, compositions comprising the same and uses thereof | |
EP2223948A4 (en) | SALT CONNECTION, INITIATOR FOR CATIONIC POLYMERIZATION AND CATIONIC POLYMERIZABLE COMPOSITION | |
IL205966A0 (en) | Oligomer-tricyclic conjugates, compositions comprising the same and uses thereof | |
IL207639A0 (en) | Pyrrolopyrimidinecarboxamide compounds, compositions comprising the same and uses thereof | |
EP2208732A4 (en) | DEHYDROXYLATED VANCOMYCIN, PREPARATION THEREOF, PHARMACEUTICAL COMPOSITION AND USE THEREOF | |
EP2133368A4 (en) | POLYMERIZABLE MONOMER, POLYMERIZABLE COMPOSITION AND DENTAL MATERIAL | |
IL213026A0 (en) | TNA-a INHIBITING PEPTIDES, COMPOSITIONS COMPRISING THE SAME AND USES THEREOF | |
IL200795A (en) | Pro-drug compounds of (+) 3-hydroxymorphine, their preparations and their use | |
EP2192122A4 (en) | Dithiolopyrrolone compounds and their preparation and use | |
ZA200706971B (en) | Substituted arylamine compounds and their use as 5-HT6 Modulators |